Mazdutide

Mazdutide — research reagent (RUO). COA per batch available.

Technical data

INN name: Mazdutide
Development code: IBI362
CAS: 2259884-03-0
Molecular formula: C210H322N46O67
Molecular weight: 4563.14 g/mol

Sizes and prices: 5 mg $1,699 MXN ($340 MXN per mg) · 10 mg $2,270 MXN ($227 MXN per mg).

Buy Mazdutide in Mexico: order online with nationwide shipping in 1-4 business days depending on zone and tracking number. Prices in Mexican pesos. Material for research use only.

Mazdutide is known internationally as Mazdutide (INN name in English). Buy Mazdutide in Mexico / buy Mazdutide in Mexico: research reagent (RUO) with COA per batch and nationwide shipping.

Mazdutida is also searched as: LY3305677, IBI362, OXM-3.

Identity and composition

Mazdutide (synonyms IBI362 y LY3305677) is a synthetic peptide studied as a dual agonist of the GLP-1 and glucagon receptors, of weekly administration, investigated mainly in contexts of obesity/overweight and type 2 diabetes. It is an acylated analog of mammalian oxyntomodulin.

As for its reference chemical identity, it is reported to have a molecular formula C207H317N45O65 and a molecular weight of 4476 g/mol (values computed in PubChem, CID 167312357). The CAS number and the complete peptide sequence are not included here because they were not confirmed in primary reference sources during the review; although they appear in supplier catalogs, they are omitted so as not to present unverified data.

Product for research use.

Mechanism of action

Mazdutide is described as a dual agonist that acts simultaneously on the GLP-1 receptor and the glucagon receptor (GCGR). Structurally it is a peptide analog of oxyntomodulin to which a fatty-acid moiety was added (acylation), a modification that seeks to prolong its persistence in the organism and make a weekly dosing compatible (PMID 36247927).

From an educational standpoint, activation of the GLP-1 receptor is associated with anorexigenic effects and improved glycemic control, whereas activation of the glucagon receptor has been linked to an increase in energy expenditure. In the available trials, a modest increase in heart rate was also observed together with a concomitant reduction in blood pressure (PMID 36247927).

Pharmacokinetics

In the phase 1b obesity trial, a terminal elimination half-life (t½) of approximately 174.8 to 1075.7 hours (that is, near 7.3 to 44.8 days), a range compatible with a weekly dosing scheme (PMID 36247927). This datum comes from an early study of limited size, so it must be interpreted as preliminary and not as a definitive parameter.

Scientific evidence

The published and confirmed evidence on mazdutide corresponds to phase 1b trials, small in size and conducted in a Chinese population, so it should be considered preliminary.

In adults with overweight or obesity, doses of 9 mg and 10 mg were investigated, observing weight reductions of up to around 11.7% at 12 weeks with the 9 mg dose (PMID 36247927).
In patients with type 2 diabetes, a reduction of HbA1c of up to approximately -2.23% and of weight close to -5% at 12 weeks was observed with doses of 4.5-6 mg (PMID 35750681).

There are also phase 2 and phase 3 trials (for example, the GLORY program) and regulatory development activity, but they were not verified against a primary source in this review and should be taken with caution. Overall, the evidence suggests an active line of research, without this constituting an established conclusion.

Research applications

Ideal for:

In vitro research studies and preclinical models on dual GLP-1/glucagon agonism.
Work on analytical characterization, receptor pharmacology and metabolic studies within the research setting.

Not applicable for:

clinical use, therapeutic use, diagnosis, or self-administration.
Any clinical application: the available evidence is preliminary and early-phase.

Product for research use. Its handling must be carried out by trained personnel in controlled laboratory settings.

Research protocols

The doses mentioned below correspond solely to regimens used in published studies and are cited for reference purposes; they do not constitute a usage recommendation.

In the phase 1b trial in overweight/obesity, weekly doses of 9 mg and 10 mg (PMID 36247927).
In the phase 1b trial in type 2 diabetes, doses in the range of 4.5-6 mg weekly (PMID 35750681).

The reported gastrointestinal effects were dose-dependent, so study protocols usually include gradual escalation. For experimental work, the specific conditions depend on each laboratory's design.

Reconstitution

As a general laboratory-handling guide, lyophilized peptides are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol as a preservative), which is suitable for preparations intended for multiple withdrawals.

Add the diluent, letting it run slowly down the wall of the vial, without directing the stream directly onto the powder.
Do not shake: gently swirl the vial until fully dissolved.
Avoid foam formation so as not to compromise the integrity of the peptide.

The diluent volume is chosen according to the working concentration desired for the experimental protocol.

Stability and storage

As a laboratory handling standard for peptides of this type:

Lyophilized (powder): it is best stored cold; refrigeration is suitable for the short term and freezing for prolonged storage. It must be protected from moisture and light.
Reconstituted (in solution): keep refrigerated and use within a limited period; it is advisable to avoid repeated freeze-thaw cycles, which can degrade the peptide.

These instructions are qualitative and for general handling; the exact conditions depend on the formulation and the laboratory protocol.

Safety profile

The documented safety profile comes from a phase 1b trial of limited size and must be interpreted with caution. In that study no serious adverse events were recorded, and the most frequent events were of mild to moderate intensity: upper respiratory infection, diarrhea, decreased appetite, nausea, and urinary tract infection; the gastrointestinal effects were dose-dependent (PMID 36247927).

A further observed a modest increase in heart rate (on the order of 11.6 to 17.4 bpm) accompanied by a reduction in blood pressure (PMID 36247927). A formal list of contraindications is not available in the consulted literature. As this is a research material, all handling must be carried out with protective equipment and under adequate laboratory practices.

Comparative context

Within its class of incretin mimetics, mazdutide is distinguished by its declared mechanism:

Unlike the pure GLP-1 agonists (for example, semaglutide), mazdutide adds the activation of the glucagon receptor.
Unlike the dual GLP-1/GIP agonists (for example, tirzepatide), the second receptor on which mazdutide acts is that of glucagon, not that of GIP.

The glucagon component seeks to increase energy expenditure in addition to the anorexigenic effect mediated by GLP-1. This comparison is qualitative and is based on the declared class of each compound; in this review no head-to-head comparison between these molecules was verified.

History and development

Mazdutide is also identified by the development codes IBI362 y LY3305677 (as well as its variants IBI-362 and LY-3305677), associated with its development by Innovent and Eli Lilly, with regulatory activity centered on China. It was designed as an acylated analog of oxyntomodulin to achieve dual agonism on the GLP-1 and glucagon receptors with weekly dosing. The confirmed primary evidence corresponds to phase 1b trials in a Chinese population with overweight/obesity and with type 2 diabetes; later phases are mentioned (including the GLORY program) as well as regulatory advances that were not verified with a primary source in this review and should be considered with caution.

FAQ

What is mazdutide and what is it researched for?

It is a synthetic peptide studied as a dual agonist of the GLP-1 and glucagon receptors, administered weekly. It has been investigated mainly in obesity/overweight and type 2 diabetes, with still preliminary phase 1b evidence. It is a product for research use, not for clinical use.

How does mazdutide differ from semaglutide or tirzepatide?

Unlike semaglutide (a pure GLP-1 agonist) or tirzepatide (a dual GLP-1/GIP agonist), mazdutide acts on the GLP-1 and glucagon receptors. The glucagon component seeks to increase energy expenditure. It is a qualitative comparison by class, without verified head-to-head studies.

How often was it administered in the studies?

Its reported terminal half-life in a phase 1b trial was approximately 7.3 to 44.8 days, a range compatible with weekly dosing (PMID 36247927). This datum is preliminary and comes from a study of limited size.

What doses were used in the trials?

In phase 1b, weekly doses of 9 mg and 10 mg were investigated in overweight/obesity (PMID 36247927) and 4.5-6 mg in type 2 diabetes (PMID 35750681). These are study doses for reference purposes, not recommendations for use.

How is it reconstituted and stored?

As a general laboratory guide, the lyophilizate is usually reconstituted with bacteriostatic water, swirling the vial gently without shaking. The powder is stored cold (refrigerated short-term, frozen long-term) and, once reconstituted, it is kept refrigerated, avoiding freeze-thaw cycles.

What adverse events were reported?

In a phase 1b trial no serious adverse events were recorded; the most frequent were mild to moderate: upper respiratory infection, diarrhea, decreased appetite, nausea and urinary infection, with dose-dependent gastrointestinal effects. A modest increase in heart rate was also observed (PMID 36247927).

Certificate of analysis per batch

Mazdutide batches with certificate of analysis published in the COA catalog:

Lot EXO010626148A — 10 mg, issued 2026-05-25
Lot EXO010626148B — 5 mg, issued 2026-05-23

Scientific references (8)

Peer-reviewed literature on Mazdutide, with its PubMed identifier when available:

Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (Ji L et al. · The New England journal of medicine · 2025) PMID 40421736.
A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity (Ji L et al. · Nature communications · 2023) PMID 38092790.
Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial (Ji L et al. · EClinicalMedicine · 2022) PMID 36247927.
A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity (Ji, et al. · Nature Communications · 2023)
Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial (Ji, et al. · eClinicalMedicine · 2022)
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. (Guo L, et al. · Nature · 2026) PMID 41407860.
Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. (Zhang B, et al. · Diabetes Care · 2024) PMID 37943529.
Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials. (Ayesh H, et al. · Am J Ther · 2024) PMID 39292847.

Full scientific profile: Mazdutide in the compendium — mechanism of action, studies and technical data sheet.

See the full category catalog: Metabolism.